The 36-month beta value for PRPH is at -0.45. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PRPH is 36.67M, and currently, shorts hold a 0.43% of that float. The average trading volume for PRPH on June 26, 2025 was 2.75M shares.
PRPH) stock’s latest price update
ProPhase Labs Inc (NASDAQ: PRPH)’s stock price has decreased by -1.43 compared to its previous closing price of 0.35. However, the company has seen a -6.11% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-26 that UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) — ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the “Extension Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the “Bid Price Requirement”), following the expiration of the initial 180 calendar days period to regain compliance on June 24, 2025. NASDAQ stated that it based its determination to grant the extension based on the Company meeting all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement.
PRPH’s Market Performance
PRPH’s stock has fallen by -6.11% in the past week, with a monthly drop of -4.44% and a quarterly drop of -28.33%. The volatility ratio for the week is 11.75% while the volatility levels for the last 30 days are 10.53% for ProPhase Labs Inc The simple moving average for the last 20 days is -2.99% for PRPH stock, with a simple moving average of -61.06% for the last 200 days.
Analysts’ Opinion of PRPH
Many brokerage firms have already submitted their reports for PRPH stocks, with H.C. Wainwright repeating the rating for PRPH by listing it as a “Buy.” The predicted price for PRPH in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on December 20, 2021 of the previous year 2021.
Dawson James gave a rating of “Buy” to PRPH, setting the target price at $25 in the report published on January 20th of the previous year.
PRPH Trading at 1.74% from the 50-Day Moving Average
After a stumble in the market that brought PRPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.16% of loss for the given period.
Stock Fundamentals for PRPH
Current profitability levels for the company are sitting at:
- -5.71 for the present operating margin
- -0.02 for the gross margin
The net margin for ProPhase Labs Inc stands at -7.88. The total capital return value is set at -1.24. Equity return is now at value -58.71, with -30.25 for asset returns.
Based on ProPhase Labs Inc (PRPH), the company’s capital structure generated 0.77 points at debt to capital in total, while cash flow to debt ratio is standing at -0.71. The debt to equity ratio resting at 3.34. The interest coverage ratio of the stock is -11.53.
Currently, EBITDA for the company is -32.34 million with net debt to EBITDA at -0.74. When we switch over and look at the enterprise to sales, we see a ratio of 5.66. The receivables turnover for the company is 0.34for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.03.
Conclusion
In conclusion, ProPhase Labs Inc (PRPH) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
